Lazard Asset Management
XBI icon

Lazard Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Lazard Asset Management’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,264
Closed -$654K – 2607
2024
Q4 		$654K Sell
7,264
-366
-5% -$35.5K ﹤0.01% 1290
2024
Q3 		$753K Buy
+7,630
New +$750K ﹤0.01% 1221

Other funds holding XBI

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Lazard Asset Management's XBI Position: Q1 2025 in Review

Lazard Asset Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2025, closing a stake of 7,264 shares — an estimated $654K sold.

Lazard Asset Management first reported a position in XBI in Q3 2024 and held it in 2 quarters. The position peaked at $753K in Q3 2024. 682 funds tracked by Wall St. Rank hold XBI as of Q1 2025.

  • Lazard Asset Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 7,264 State Street SPDR S&P Biotech ETF shares in Q1 2025, an estimated $654K.
  • Lazard Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2024 and held it in 2 quarters.
  • Lazard Asset Management's State Street SPDR S&P Biotech ETF position peaked at $753K in Q3 2024.
  • 682 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.